PCVX Vaxcyte, Inc. Common Stock
XNAS 66.93 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PCVX
$66.93
—
What changed
Recent filings, trades and movesKey stats
$66.93
- 52-Week Range
- $41.44 – $90.75
- YTD
- +44.06%
- IV Rank (30D)
- 13.01
- Straddle Price
- $9.25
- P/C Vol Ratio
- 0.80
- Market Cap
- $10.1B
- Open
- $64.75
- Day Range
- $63.93 – $67.20
- Volume
- 529,369
- Prev Close
- $63.89
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.10 |
| Cost of Equity (CAPM) | 10.11% (VRP-adj) |
| WACC | 10.56% |
| Volatility Risk Premium | -15.6pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.9B |
| Return on Equity (TTM) | -38.6% |
| Book / Price | 29.9% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $61.71 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $63.50 |
| Bollinger Width / SMA20 | 17.2% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $9B |
Peers used for multiples: GILD, ISRG, LLY, MDGL, NTRA, RVMD, RYTM, UNH
60-Day Conviction
9%
20-Day Fair Value
≈ by Dec 8, 2026
$66.92
α -0.3%
rank 90%
conviction
24%
40-Day Fair Value
≈ by Jan 6, 2027
$67.43
α +0.4%
rank 90%
conviction
18%
60-Day Fair Value
≈ by Feb 4, 2027
$66.90
α -0.4%
rank 90%
conviction
9%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 44.1× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 31.8× · 4 peers |
| Peer P/B | $304.82 | 14% | median 16.0× · 8 peers |
| Peer P/S | n/a | 0% | median 14.2× · 8 peers |
| Market Anchor (SMA50) | $61.71 | 49% | stability 68% (BB-width) |
| Options Expected (B-L 30d) | $64.03 | 36% | 21 strikes · skew +0.26 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $10.1B
- Employees
- 507
- List Date
- 2020-06-12
- CIK
- 0001649094
- Last Earnings
- Nov 4 after close · −5.7% vs ±12.0% expected
- Next Earnings
- ~Feb 23, 2027 (estimated)
- Headquarters
- San Carlos, CA
- Homepage
- https://www.vaxcyte.com
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -9.18% | -27.55% | -3.92% | 13.47% | 6.03% | 15.30% | -0.97% |
| Feb | -4.85% | 20.49% | -7.81% | -2.26% | -13.90% | 7.56% | -0.13% |
| Mar | -23.54% | 1.30% | -10.06% | -4.74% | -47.63% | -6.24% | -15.15% |
| Apr | -11.28% | 1.68% | 12.74% | -9.26% | 11.20% | -2.15% | 0.49% |
| May | 13.95% | -4.42% | 2.61% | 10.30% | -7.80% | -9.71% | 0.82% |
| Jun | 6.63% | -4.14% | -0.72% | 4.53% | -7.17% | 18.85% | 3.00% |
| Jul | -5.57% | 6.41% | -2.34% | 2.53% | 3.07% | -3.40% | 0.12% |
| Aug | 16.68% | 14.59% | 5.29% | 2.76% | -6.75% | 13.47% | 7.67% |
| Sep | -5.61% | -6.72% | -3.99% | 3.74% | 14.13% | -6.43% | -0.81% |
| Oct | -10.79% | 79.98% | -1.92% | -7.95% | 19.06% | 10.67% | 14.84% |
| Nov | -18.45% | 2.36% | 7.88% | -12.07% | 15.83% | 10.82%* | 1.06% |
| Dec | 16.28% | 5.38% | 16.71% | -10.63% | 1.36% | -- | 5.82% |
| Total | -37.34% | 81.92% | 11.54% | -12.61% | -30.23% | 53.58% | 11.14% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $63.32
SMA 50: $61.85
SMA 200: $57.44
Current: $67.03
EMA 12: $63.38
EMA 26: $62.95
MACD: 0.4234 | Signal: 0.2199
BULLISH
ADX (14): 26.50
TREND
+DI: 28.26
−DI: 14.80
Momentum Oscillators
RSI (14): 57.74
NEUTRAL
Stoch %K: 61.51
Stoch %D: 53.54
Williams %R: -5.26
Volume & Volatility
BB Upper: $68.01
BB Lower: $58.62
NEUTRAL
OBV: -7,385,690
Vol SMA 20: 2,137,627
Vol ROC: -64.23%
ATR: $3.59
True Range: $3.31
HV 20: 56.7%
HV 30: 100.6%
HV 60: 74.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before PCVX’s Nov 4 earnings report, so it doesn’t reflect the results.
Here is the LLM Stock Analysis Report for PCVX:
Executive Summary
Overall assessment: NEUTRAL with confidence level (6/10)
Key drivers and primary risks:
- Recent positive news headlines and strong technical signals have driven the stock higher, but volatility remains moderate.
- The company's pneumococcal vaccine program has shown promise in recent studies, which could drive future growth.
- Risks include potential regulatory hurdles and competition from established players.
Recent news sentiment impact: The majority of recent news headlines are positive (4 out of 6), with a neutral headline from the industry publication Benzinga. This suggests that investor sentiment is generally optimistic.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Uptrend, Medium-term (1-3 months): Uptrend, Long-term (3-12 months): Downtrend
Support/Resistance Levels: Key price levels from moving averages and technical patterns: + SMA 20: $55.82 + SMA 50: $53.71 + SMA 200: $52.38 + Upper Bollinger Band: $58.74 + Lower Bollinger Band: $52.89
Momentum Signals: * RSI interpretation (overbought >70, oversold <30, neutral 30-70): Neutral (57.77) * MACD signal (bullish/bearish crossover): Bullish * Bollinger Bands position (squeeze, breakout, mean reversion): Mean reversion
Volume Analysis: Volume trends and institutional interest signals: + Volume SMA 20: 891289.75 + On-Balance Volume (OBV): -13901558.88 + Volume Rate of Change: -19.51%
News & Sentiment Analysis
Recent Headlines Summary: The majority of recent news headlines are positive, highlighting the company's pneumococcal vaccine program and financing activities.
Sentiment Assessment: Aggregate news sentiment is Positive (4 out of 6).
Catalyst Identification: Upcoming earnings release and continued progress in the pneumococcal vaccine program could drive future growth.
Market Narrative: The positive news headlines have driven the stock higher, but volatility remains moderate. The market narrative suggests that investors are optimistic about the company's prospects.
Risk & Volatility Assessment
Beta Interpretation: Beta: 0.89 (vs SPY) - indicates a relatively stable stock with low risk relative to the market.
Volatility Regime: Current vs historical volatility levels: + Historical Volatility (HV30): 48.1% + IV Premium vs HV30: 33.3% (positive = implied richer than realized) + Stock Volatility: 0.46
Options Market Signals: IV Rank: 2.1% (Low - shows if volatility is historically high/low), Current IV: 64.1%, Expected Move: $7.27 (39 DTE)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: + Sector: Healthcare + Market: S&P 500 (0.89 beta, moderate volatility)
Institutional Activity: Volume patterns suggesting institutional interest: + Volume SMA 20: 891289.75 + On-Balance Volume (OBV): -13901558.88
Correlation Analysis: How stock moves relative to market (R-squared interpretation): + R-squared: 0.25 (low correlation, high volatility)
Relative Valuation: Position within trading range: + Current Price: $58.29 + SMA 20: $55.82 + Upper Bollinger Band: $58.74
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor: + Lower Bollinger Band: $52.89 + SMA 50: $53.71 + SMA 200: $52.38
Breakout/Breakdown Levels: Technical levels that could trigger significant moves: + Upper Bollinger Band: $58.74
Time-Sensitive Catalysts: Earnings release and continued progress in the pneumococcal vaccine program.
Risk Management: Stop-loss levels and position sizing considerations: + Use a stop-loss order at $55.82 (SMA 20) to limit potential losses. + Consider reducing position size if IV Rank falls below 1% or IV Premium vs HV30 increases above 50%.
Please let me know if you would like me to modify anything!
Generated
News
All PCVX news →
Earnings History
16 of 18 under expected move
Avg Expected Move
11.96%
Avg Actual Move
5.24%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-29 | After-Close | 12.54% | 17.91% | 1.43x | Exceeded |
| 2022-02-28 | After-Close | 24.21% | 2.89% | 0.12x | Within |
| 2022-11-07 | After-Close | 11.58% | 3.34% | 0.29x | Within |
| 2023-02-27 | After-Close | 11.35% | 3.14% | 0.28x | Within |
| 2023-05-08 | After-Close | 6.64% | 4.76% | 0.72x | Within |
| 2023-08-08 | After-Close | 7.02% | 3.93% | 0.56x | Within |
| 2023-11-06 | After-Close | 8.81% | 4.15% | 0.47x | Within |
| 2024-05-08 | After-Close | 9.40% | 1.83% | 0.19x | Within |
| 2024-08-06 | After-Close | 9.91% | 4.61% | 0.47x | Within |
| 2024-11-05 | After-Close | 6.25% | 3.24% | 0.52x | Within |
| 2025-02-25 | After-Close | 19.09% | 0.88% | 0.05x | Within |
| 2025-05-07 | After-Close | 13.97% | 8.45% | 0.60x | Within |
| 2025-08-06 | After-Close | 11.74% | 9.06% | 0.77x | Within |
| 2025-11-04 | After-Close | 19.83% | 2.49% | 0.13x | Within |
| 2026-02-24 | After-Close | 12.43% | 2.75% | 0.22x | Within |
| 2026-05-06 | After-Close | 8.36% | 9.84% | 1.18x | Exceeded |
| 2026-08-05 | After-Close | 10.15% | 5.31% | 0.52x | Within |
| 2026-11-04 | After-Close | 12.03% | 5.72% | 0.48x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PCVX Options Activity & IV Rank
PCVX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 53.8%
7-DTE IV: 62.0%
Expected Move: $9.25
7-DTE Move: $5.75
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,281
Put Volume: 1,024
P/C Volume: 0.799
NEUTRAL
Call OI: 41,880
Put OI: 55,103
P/C OI: 1.316
Total OI: 96,983
ATM Options Pricing
ATM Call: $5.55
ATM Put: $3.70
Call %: 8.3%
Put %: 5.5%
Chain Summary
Chain Volume: 2,305
Chain OI: 96,983
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
49%
vs own history
GEX tilt
+0.06
OI-weighted, today
Vanna tilt
+0.62
δ-sensitivity to IV
Charm tilt
-0.80
δ-decay vs time
Vanna tilt +0.62: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.80: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 20 ATM contracts, 12k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)21.4LowNov 9
IV Rank (30 DTE)13.0LowNov 9
Straddle Price (30 DTE)$9.25Nov 9
Beta Analysis
Risk Metrics
Beta: 1.2259
Alpha: 47.65%
Correlation: 0.3004
R-Squared: 9.0%
Stock Volatility: 56.1%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PCVX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $7.9M | #1755 of 3716 | -53.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.9M | #602 of 997 | +289.2% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.1M | #2251 of 3138 | -64.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $589K | #2002 of 4729 | +2.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PCVX Institutional Ownership (13F)
Filings for 2026-06-30 · 128 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 139,071,701 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
13 filers$122.48M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $47.24M | 38.57% | 2026-06-30 |
| 2 | Caption Management, LLC | $37.77M | 30.84% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $14.88M | 12.15% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $10.56M | 8.62% | 2026-06-30 |
| 5 | DIADEMA PARTNERS LP | $3.09M | 2.52% | 2026-06-30 |
| 6 | Nantahala Capital Management, LLC | $2.05M | 1.67% | 2026-06-30 |
| 7 | TUDOR INVESTMENT CORP ET AL | $1.87M | 1.52% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $1.66M | 1.35% | 2026-06-30 |
| 9 | Goldman Sachs Group Inc Custodian | $1.46M | 1.19% | 2026-06-30 |
| 10 | SIG BROKERAGE, LP | $906.83K | 0.74% | 2026-06-30 |
| 11 | Simplex Trading, LLC Custodian | $642.97K | 0.53% | 2026-09-30 |
| 12 | Persistent Asset Partners Ltd | $248.56K | 0.20% | 2026-06-30 |
| 13 | Walleye Capital LLC | $116.26K | 0.09% | 2026-06-30 |
11 filers$233.95M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $72.93M | 31.17% | 2026-06-30 |
| 2 | Caption Management, LLC | $60.87M | 26.02% | 2026-06-30 |
| 3 | BOOTHBAY FUND MANAGEMENT, LLC | $35.73M | 15.27% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $35.16M | 15.03% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $10.26M | 4.39% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $9.14M | 3.91% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $5.76M | 2.46% | 2026-09-30 |
| 8 | DIADEMA PARTNERS LP | $2.84M | 1.22% | 2026-06-30 |
| 9 | SIG BROKERAGE, LP | $906.83K | 0.39% | 2026-06-30 |
| 10 | Walleye Capital LLC | $313.90K | 0.13% | 2026-06-30 |
| 11 | Persistent Asset Partners Ltd | $31.29K | 0.01% | 2026-06-30 |
PCVX Insider Trading (Form 4)
Latest: 2026-11-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-04 | Elvia Cowan | SVP, Finance & CAO | Mixed Sell −3,000 · Exer +3,000 |
— | $43.42 | -$105.0K | EDGAR |
| 2026-11-04 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Mixed Sell −2,250 · Exer +2,250 |
— | $33.12 | -$125.0K | EDGAR |
| 2026-10-07 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Mixed Exer +18,000 · Sell −18,000 |
— | $46.05 | -$1.47M | EDGAR |
| 2026-10-07 | Elvia Cowan | SVP, Finance & CAO | Mixed Exer +19,000 · Sell −19,000 |
— | $56.33 | -$1.16M | EDGAR |
| 2026-10-02 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Mixed Sell −2,250 · Exer +2,250 |
— | $31.01 | -$115.5K | EDGAR |
| 2026-09-09 | Elvia Cowan | SVP, Finance & CAO | Tax (F) | −1,327 | $60.36 | -$80.1K | EDGAR |
| 2026-09-09 | Andrew Guggenhime | PRESIDENT AND CFO | Tax (F) | −7,155 | $60.36 | -$431.9K | EDGAR |
| 2026-09-09 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Mixed Sell −2,715 · Tax −5,459 |
−8,174 | $60.36 | -$493.4K | EDGAR |
| 2026-09-09 | Luis Jodar | Chief Medical Officer | Award (A) | +52,632 | — | EDGAR | |
| 2026-09-09 | Grant Pickering | CHIEF EXECUTIVE OFFICER | Tax (F) | −17,056 | $60.36 | -$1.03M | EDGAR |
| 2026-09-09 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Tax (F) | −7,651 | $60.36 | -$461.8K | EDGAR |
| 2026-09-02 | Elvia Cowan | SVP, Finance & CAO | Tax (F) | −569 | $61.22 | -$34.8K | EDGAR |
| 2026-09-02 | Andrew Guggenhime | PRESIDENT AND CFO | Tax (F) | −2,705 | $61.18 | -$165.5K | EDGAR |
| 2026-09-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Tax (F) | −1,020 | $61.28 | -$62.5K | EDGAR |
| 2026-09-02 | Jim Wassil | CHIEF OPERATING OFFICER | Mixed Exer +2,250 · Tax −2,705 · Sell −3,477 |
−3,932 | $46.24 | -$365.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PCVX Insider Holdings
15 insiders · @ $67.03
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Grant Pickering | CHIEF EXECUTIVE OFFICER | 563,117 | $37.75M | -$39.81M | 79 | 2026-09-09 |
| 2 | Andrew Guggenhime | PRESIDENT AND CFO | 157,166 | $10.53M | -$18.70M | 51 | 2026-09-09 |
| 3 | Jim Wassil | EVP, Chief Scientific Ofc, COO | 145,778 | $9.77M | -$13.02M | 56 | 2026-11-04 |
| 4 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | 68,085 | $4.56M | -$1.39M | 13 | 2026-09-09 |
| 5 | Luis Jodar | Chief Medical Officer | 52,632 | $3.53M | $0 | 1 | 2026-09-09 |
| 6 | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | 41,732 | $2.80M | -$6.10M | 27 | 2025-03-07 |
| 7 | Elvia Cowan | SVP, Finance & CAO | 30,860 | $2.07M | -$5.05M | 21 | 2026-11-04 |
| 8 | Heath Lukatch | Director | 19,481 | $1.31M | -$1.94M | 15 | 2026-06-16 |
| 9 | Anne S Drapeau | Director | 12,481 | $836.6K | $0 | 6 | 2026-06-16 |
| 10 | Halley E Gilbert | Director | 12,481 | $836.6K | -$1.33M | 7 | 2026-06-16 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PCVX Board & Officers
As of SEC filings through Nov 4, 2026Directors 10
- Grant Pickering · since Jun 11, 2020
- Halley E Gilbert · since Jun 11, 2020
- Heath Lukatch · since Jun 11, 2020
- Moncef Slaoui · since Jun 11, 2020
- Anne S Drapeau · since Sep 16, 2021
- Teri Loxam · since Sep 16, 2021
- Carlos V Paya · since Oct 27, 2021
- John Furey · since Jul 2, 2024
- Olivier Brandicourt · since May 1, 2025
- John Markels · since Jul 16, 2026
Officers 6
- Grant Pickering · Chief Executive Officer · listed since Apr 2021
- Andrew Guggenhime · President and CFO · listed since Apr 2021
- Jim Wassil · EVP, Chief Scientific Ofc, COO · listed since Sep 2026
- Harpreet S. Dhaliwal · Chief Technical Ops Officer · listed since Apr 2025
- Luis Jodar · Chief Medical Officer · since Aug 31, 2026
- Elvia Cowan · SVP, Finance & CAO · listed since Mar 2026
Changes in the last 10 years (57)
| Sep 9, 2026 | Jim Wassil listed as EVP, Chief Scientific Ofc, COO (previously Chief Operating Officer) in SEC filings |
| Aug 31, 2026 | Luis Jodar became Chief Medical Officer |
| Jul 16, 2026 | John Markels became a director |
| Jun 17, 2026 | The company announced the departure of Jacks Lee from the board in an SEC filing |
| Mar 2, 2026 | Elvia Cowan listed as SVP, Finance & CAO (previously SVP, Finance) in SEC filings |
| May 1, 2025 | Olivier Brandicourt became a director |
| Apr 25, 2025 | Harpreet S. Dhaliwal first listed as Chief Technical Ops Officer in an SEC filing |
| Jul 2, 2024 | John Furey became a director |
| Nov 27, 2023 | Jacks Lee became a director |
| Mar 3, 2023 | Elvia Cowan listed as SVP, Finance (previously SVP, Finance and Principal Accounting Officer) in SEC filings |
| Jan 4, 2023 | Paul Sauer reported in an SEC filing no longer being SVP Process Dev, Manufacturing |
| Jan 4, 2023 | Jeff Fairman reported in an SEC filing no longer being VP, Research |
| Jan 4, 2023 | Harpreet S. Dhaliwal reported in an SEC filing no longer being SVP Cml Mfg & Supply Chain |
| Jan 1, 2023 | Elvia Cowan became SVP, Finance and Principal Accounting Officer |
| Apr 1, 2022 | Mikhail Eydelman became SVP, Gen Counsel & Corp Sec |
| Oct 27, 2021 | Michael E. Kamarck became a director |
| Oct 27, 2021 | Carlos V Paya became a director |
| Oct 1, 2021 | Harpreet S. Dhaliwal became SVP Cml Mfg & Supply Chain |
| Sep 16, 2021 | Teri Loxam became a director |
| Sep 16, 2021 | Anne S Drapeau became a director |
| Apr 6, 2021 | Grant Pickering listed as Chief Executive Officer (previously President & CEO) in SEC filings |
| Apr 6, 2021 | Andrew Guggenhime listed as President and CFO (previously CFO, Cbo) in SEC filings |
| Jan 8, 2021 | Robert Lorne Hopfner reported in an SEC filing no longer being a director |
| Dec 17, 2020 | TPG Group Holdings (SBS) Advisors, Inc. reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2020 | James G Coulter reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2020 | David Bonderman reported in an SEC filing no longer being a 10% owner |
| Oct 9, 2020 | Rajeev M. Shah reported in an SEC filing no longer being a 10% owner |
| Oct 9, 2020 | Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 9, 2020 | RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner |
| Oct 9, 2020 | Peter Kolchinsky reported in an SEC filing no longer being a 10% owner |
| Jun 16, 2020 | Rajeev M. Shah became a 10% owner |
| Jun 16, 2020 | Ra Capital Management, L.p. became a 10% owner |
| Jun 16, 2020 | RA Capital Healthcare Fund LP became a 10% owner |
| Jun 16, 2020 | Peter Kolchinsky became a 10% owner |
| Jun 11, 2020 | William J Newell became a director |
| Jun 11, 2020 | TPG Group Holdings (SBS) Advisors, Inc. became a 10% owner |
| Jun 11, 2020 | Robert Lorne Hopfner became a director |
| Jun 11, 2020 | Peter Hirth became a director |
| Jun 11, 2020 | Paul Sauer became SVP Process Dev, Manufacturing |
| Jun 11, 2020 | Patrick J Heron became a director |
| Jun 11, 2020 | Patrick G Enright became a 10% owner |
| Jun 11, 2020 | Moncef Slaoui became a director |
| Jun 11, 2020 | Longitude Venture Partners II, L.P. became a 10% owner |
| Jun 11, 2020 | Longitude Capital Partners II, LLC became a 10% owner |
| Jun 11, 2020 | Kurt Von Emster became a director |
| Jun 11, 2020 | Jim Wassil became Chief Operating Officer |
| Jun 11, 2020 | Jeff Fairman became VP, Research |
| Jun 11, 2020 | Jane Wright-Mitchell became General Counsel |
| Jun 11, 2020 | James G Coulter became a 10% owner |
| Jun 11, 2020 | Heath Lukatch became a director |
| Jun 11, 2020 | Halley E Gilbert became a director |
| Jun 11, 2020 | Grant Pickering became a director |
| Jun 11, 2020 | Grant Pickering became President & CEO |
| Jun 11, 2020 | David Bonderman became a 10% owner |
| Jun 11, 2020 | Bakker Juliet Tammenoms became a 10% owner |
| Jun 11, 2020 | Andrew Guggenhime became CFO, Cbo |
| Jun 11, 2020 | Abingworth LLP became a 10% owner |
Not reported recently (12)
- Mikhail Eydelman · Last reported as SVP, Gen Counsel & Corp Sec in an SEC filing dated Mar 7, 2025
- Peter Hirth · Last reported as a director in an SEC filing dated Jun 10, 2024
- Michael E. Kamarck · Last reported as a director in an SEC filing dated Jun 15, 2023
- Jane Wright-Mitchell · Last reported as General Counsel in an SEC filing dated Aug 18, 2021
- Kurt Von Emster · Last reported as a director in an SEC filing dated Jun 3, 2021
- Patrick J Heron · Last reported as a director in an SEC filing dated Jun 3, 2021
- William J Newell · Last reported as a director in an SEC filing dated Dec 10, 2020
- Abingworth LLP · Last reported as a 10% owner in an SEC filing dated Jun 16, 2020
- Longitude Venture Partners II, L.P. · Last reported as a 10% owner in an SEC filing dated Jun 11, 2020
- Longitude Capital Partners II, LLC · Last reported as a 10% owner in an SEC filing dated Jun 11, 2020
- Patrick G Enright · Last reported as a 10% owner in an SEC filing dated Jun 11, 2020
- Bakker Juliet Tammenoms · Last reported as a 10% owner in an SEC filing dated Jun 11, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PCVX Proposed Insider Sales (Form 144)
Latest: 2026-11-02
? Form 144 Guide
Last 30d:
2 filings
· $325K notice value
· Last 90d:
8 filings
· $4.0M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Wassil Jim (6, $2.2M) · Cowan Elvia (2, $1.8M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | Wassil Jim | Officer | 2,250 | $139.2K | 2026-11-02 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-11-02 | Cowan Elvia | Officer | 3,000 | $185.6K | 2026-11-02 | UBS Financial Services, Inc | 10b5-1 | EDGAR |
| 2026-10-05 | Cowan Elvia | Officer | 19,000 | $1.65M | 2026-10-05 | UBS Financial Services, Inc | 10b5-1 | EDGAR |
| 2026-10-05 | Wassil Jim | Officer | 18,000 | $1.56M | 2026-10-05 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-10-01 | Wassil Jim | Officer | 2,250 | $127.6K | 2026-10-01 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-09-09 | Wassil Jim | Officer | 1,334 | $80.0K | 2026-09-09 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-09-04 | Wassil Jim | Officer | 1,381 | $82.5K | 2026-09-04 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-09-01 | Wassil Jim | Officer | 3,477 | $209.6K | 2026-09-01 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-08-05 | Dhaliwal Harpreet S. | Officer | 17,000 | $935.0K | 2026-08-05 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-08-03 | GUGGENHIME ANDREW | Officer | 10,000 | $539.9K | 2026-08-03 | UBS Financial Services, Inc | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Earnings results | EDGAR |
| 2026-10-09 | Material agreement · New debt obligation · Other events | EDGAR |
| 2026-10-05 | Regulation FD disclosure · Other events | EDGAR |
| 2026-09-03 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-07-15 | Director or officer change | EDGAR |
| 2026-06-23 | Director or officer change | EDGAR |
| 2026-06-16 | Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
94 ETFs hold PCVX
25 shown · $1.44B total exposure · 0.24% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $271.3M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.30% | $229.6M | $76.6B | 2026-11-06 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.11% | $190.6M | — | 2026-09-30 |
| 4 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.27% | $127.5M | $10.0B | 2026-11-05 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.24% | $105.9M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.09% | $87.8M | — | 2026-09-30 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.64% | $70.2M | $11.1B | 2026-11-06 |
| 8 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.41% | $56.5M | $13.7B | 2026-11-06 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.25% | $43.6M | — | 2026-09-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.17% | $38.0M | — | 2026-08-31 |
| 11 | TCAF T. Rowe Price Capital Appreciation Equity ETF | Nport | 0.50% | $37.2M | — | 2026-06-30 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.10% | $34.8M | — | 2026-11-05 |
| 13 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.20% | $27.2M | $13.9B | 2026-11-06 |
| 14 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.15% | $22.1M | — | 2026-08-31 |
| 15 | VHT Vanguard Health Care ETF | Vanguard | 0.10% | $21.3M | — | 2026-09-30 |
| 16 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.02% | $17.7M | — | 2026-11-05 |
| 17 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $11.8M | $93.2B | 2026-11-06 |
| 18 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.12% | $8.2M | $6.6B | 2026-11-05 |
| 19 | VT Vanguard Total World Stock ETF | Vanguard | 0.01% | $6.2M | — | 2026-09-30 |
| 20 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.20% | $5.5M | — | 2026-06-30 |
| 21 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.33% | $5.5M | — | 2026-09-30 |
| 22 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.01% | $4.7M | — | 2026-08-31 |
| 23 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.89% | $4.6M | — | 2026-11-06 |
| 24 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.16% | $4.4M | — | 2026-07-31 |
| 25 | RSSL Global X Russell 2000 ETF | Global X | 0.30% | $4.2M | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-7.63
TTM Revenue
—
TTM Net Income
$-1.06B
TTM Op. Cash Flow
$-881.23M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-284.30M | $-1.97 | $-232.47M |
| Q1 '26 | 2026-03-31 | — | $-320.62M | $-2.30 | $-280.62M |
| Q4 '25 | 2025-12-31 | — | $-246.51M | $-1.80 | $-224.83M |
| Q3 '25 | 2025-09-30 | — | $-212.83M | $-1.56 | $-143.31M |
| Q2 '25 | 2025-06-30 | — | $-166.57M | $-1.22 | $-121.17M |
| Q1 '25 | 2025-03-31 | — | $-140.72M | $-1.04 | $-166.27M |
| Q4 '24 | 2024-12-31 | — | $-137.08M | $-1.02 | $-111.40M |
| Q3 '24 | 2024-09-30 | — | $-103.12M | $-0.83 | $-60.71M |
| Q2 '24 | 2024-06-30 | — | $-128.70M | $-1.10 | $-121.39M |
| Q1 '24 | 2024-03-31 | — | $-95.02M | $-0.85 | $-159.12M |
| Q4 '23 | 2023-12-31 | — | $-180.80M | $-1.82 | $-128.81M |
| Q3 '23 | 2023-09-30 | — | $-92.66M | $-0.91 | $-57.55M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.39
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-38.6%
ROA
-33.9%
Div Yield
0.00%
FCF Yield
-9.43%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$9.34B
as of 2026-11-09
PCVX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.9 | +45.5% | +31.0% | 27 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $353.2B | 30.0 | +9.7% | +18.0% | 45 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| ISRG Intuitive Surgical Inc. | $160.0B | 55.8 | +20.5% | −17.9% | 18 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.5% | 65 |
| PCVX Vaxcyte, Inc. Common Stock | $10.1B | — | — | +44.3% | 13 |
| MDGL Madrigal Pharmaceuticals, Inc. Common St | $9.3B | — | +92.8% | −27.5% | 54 |
| RYTM Rhythm Pharmaceuticals, Inc. Common Stoc | $7.8B | — | +61.0% | +7.6% | 66 |
| Peer median | $102.5B | 45.9 | +36.6% | +24.5% | 47 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
14.62M
SI % of Float
11.20%
Days to Cover
2.89
Short Vol Ratio
40.3%
Free Float
130.56M
Float %
87.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24